Praluent Shortage: What Providers and Prescribers Need to Know in 2026

Praluent (alirocumab) is not on the FDA or ASHP drug shortage lists as of 2026, but patient access challenges are clinically significant and frequently cited by prescribers. This briefing reviews the current access landscape, prior authorization strategies, formulary considerations, and practical alternatives to help your practice minimize treatment disruptions for patients who need PCSK9 inhibitor therapy.

Current Access Landscape: What's Driving the Problem

Praluent's access challenges are systemic rather than supply-based. As a biologic specialty medication requiring cold-chain distribution, most retail pharmacies don't maintain inventory. Distribution flows primarily through specialty pharmacy networks — Accredo, CVS Specialty, Walgreens Specialty, and others — with plan-mandated channeling adding administrative complexity.

Key access barriers your patients face in 2026:

Prior authorization: Required by virtually all commercial and Part D plans. Initial denial rates remain high. Complete clinical documentation submitted with the initial request significantly reduces back-and-forth.

Formulary competition: Approximately 50% of commercial plans cover Praluent; others require Repatha (evolocumab) as the preferred PCSK9 inhibitor, or may exclude both pending step therapy through ezetimibe.

Medicare gap: Manufacturer copay cards are prohibited for Medicare patients. The $2,100 Part D out-of-pocket cap helps, but Medicare beneficiaries may still face substantial costs until reaching the cap.

Specialty pharmacy delays: Even after PA approval, specialty pharmacy processing, shipping, and cold-chain delivery can take 5–10 business days. Patients who run out before the next delivery can miss injections.

Prior Authorization Strategies That Improve Approval Rates

The single most effective intervention is submitting a complete, well-documented initial PA request. Denials most commonly occur when documentation is incomplete. Include:

Primary diagnosis: Established ASCVD (ICD-10: I25.10, I63.9, Z87.39, etc.) or confirmed HeFH/HoFH (ICD-10: E78.01, E78.00)

Evidence of maximally tolerated statin therapy: specific statin name, dose, duration, and reason for "maximal" designation (including any dose-limiting side effects)

Current LDL-C value with lab date (above plan threshold: typically 70 mg/dL for ASCVD, 100 mg/dL for FH primary prevention)

Ezetimibe trial documentation (name, dose, duration, and response or reason for intolerance) — required by most plans before PCSK9 inhibitor approval

Clinical rationale statement: brief note explaining why Praluent is indicated for this patient at this time

For PA denials, peer-to-peer review with the plan's medical director is often the fastest path to reversal. Document cardiovascular risk quantitatively (10-year ASCVD risk score if available) and specify the clinical urgency for PCSK9 inhibition.

Formulary Navigation: Praluent vs. Repatha

Clinically, Praluent and Repatha are highly similar: both reduce LDL-C by 50–65% on top of statins and demonstrated approximately 15% relative reductions in MACE in their respective outcome trials (ODYSSEY OUTCOMES and FOURIER). Formulary choice typically reflects rebate negotiations rather than clinical differentiation.

Practical recommendation: Before prescribing, check your patient's formulary. If Repatha is preferred and there's no specific clinical reason to use Praluent, prescribing the preferred agent avoids PA appeals and reduces cost burden for the patient. The ODYSSEY and FOURIER outcomes data are comparable.

Clinical Alternatives to Consider

If Praluent access cannot be resolved in a clinically acceptable timeframe, consider:

Leqvio (inclisiran): Twice-yearly in-office injection. Covered under Part B for Medicare patients (bypassing Part D formulary restrictions). Achieves ~50% LDL-C reduction. Useful for adherence-challenged patients.

Bempedoic acid (Nexletol): Oral, once-daily. Reduces LDL-C by 15–25% added to statins. CLEAR Outcomes demonstrated cardiovascular event reduction in statin-intolerant patients. Available at retail pharmacies. Carries gout risk.

Ezetimibe: Generic available, ~$15–$40/month, 18–25% additional LDL-C reduction. Consider as a bridge if PCSK9 inhibitor access is delayed and patient's LDL-C is marginally above goal.

39,483+ patients found their medications in stock

39K+

Find Praluent In Stock Today →

Patient Support Resources to Reduce Administrative Burden

Directing patients to the right resources early reduces call-backs and repeat PA submissions:

MyPRALUENT Copay Card: Commercially insured patients may pay $35–$50/month; call 1-844-772-5836

MyPraluent PAP: Uninsured/underinsured patients may receive Praluent at no cost; income-based eligibility

medfinder for providers: Direct your patients to medfinder.com/providers — a pharmacy-locating service that calls pharmacies to find which ones have Praluent in stock, reducing patient burden and time-to-fill.

Clinical Bottom Line

Praluent is not in a manufacturing shortage, but systemic access barriers mean that many clinically appropriate patients don't receive this therapy on schedule. Proactive PA documentation, formulary verification before prescribing, and early enrollment in patient assistance programs are the most effective interventions. For more on supporting patients with access, see our provider guide to helping patients find Praluent in stock.